Pharmacovigilance Lawbreakers Could Lose Drug License Under Australia’s New Inspection Program
Executive Summary
Pharmacovigilance inspections are to commence soon under a new program the Therapeutic Goods Administration has implemented to strengthen and broaden its post-market monitoring activities. Inspections will be mainly limited to Australian affiliate sites, though overseas sites might be inspected too.
You may also be interested in...
Australia To Identify High-Risk Companies Ahead Of First Pharmacovigilance Inspections
As Australia moves ahead with introducing UK-style pharmacovigilance inspections, it is calling on drug sponsors to complete a risk assessment survey to help it prioritize its work. Non-responsive companies will be assigned the highest risk score under this exercise.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.
EU CHMP Opinions And MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.